BridgeBio Pharma

We don't hope for breakthroughs. We build toward them. At #MIGlobal, our CEO and Co-Founder Neil Kumar joined @Bloomberg live to talk about what focused execution looks like in practice – targeting genetic disease at the source, with 3 therapies through FDA approval and 3 more potentially through the FDA in the next 12 months. Every minute counts and we're just getting started.

Two milestones for #ADH1: CALIBRATE Phase 3 primary data at #ECE2026 and our NDA is now submitted to the FDA. A first-ever approved therapy for ADH1 could soon be a reality. Learn more: bit.ly/432ELU8

We are thrilled to share new data for ATTR-CM in clinical outcomes, biomarkers, and functional capacity in one late-breaking oral presentation, two moderated eposters, and two posters at #HeartFailure26. Learn more: bit.ly/4eB23Yu

This Mother's Day, we're thinking of every mom, who has ever had to explain the unexplainable, advocate in rooms that weren't ready to listen, and still show up with hope. We wish all mothers a day filled with appreciation and joy. Watch our the Mothers of Resilience video developed by the CureLGMD2i Foundation and supported by BridgeBio, to see Mothers who exemplify this: bit.ly/4fbzdxP

Thank you to @patientaccess for hosting the Rare Disease Working Group. Clinicians and patient advocates came together to identify access barriers and align on policies that protect patients' ability to get the care they need. This is the work that moves the needle.

We exist to develop transformative medicines for genetic conditions. Today, we announced our financial results for the first quarter in 2026 and provided an update on our commercial progress. Learn more: bit.ly/4u3vAyU

10,000+ rare diseases. 30 million Americans affected. The data matters, but our Founder & CEO Neil Kumar reminded us at #MIGlobal why the stories matter more. Watch the full @MilkenInstitute panel: bit.ly/42edSML

We are thrilled to share that our near-complete TTR stabilizer for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) is now approved in Brazil. Learn more: bit.ly/4teBX0O

We’re heading to @ESEndocrinology’s #ECE2026 (May 9–12, Prague). New data from CALIBRATE, our Phase 3 study of encaleret in ADH1, will be presented in an oral session. BridgeBio will also share an additional oral presentation, plus a poster and ePoster. Learn more: bit.ly/4uqLi6U

10,000+ rare diseases. One-at-a-time models aren't working. This year at #MIGlobal, our Founder and CEO Neil Kumar, Ph.D. joins others, with moderator @BeckyQuick of @CNBC, on stage to discuss how AI, platform therapies, and smarter regulatory models are rewriting the rules for the rare disease community. Learn more: milkeninstitute.org/events/global-…

We’re looking forward to sharing new data from the Phase 3 ATTRibute-CM study at #HeartFailure26 in Barcelona (May 9–12), including a late-breaking oral presentation. Learn more: bit.ly/4ujdOHm

We're at #PES2026 with three booths & four skeletal dysplasias posters on site. Come find us!

Every extra minute on the wrong path is time patients don't get back. 10,000+ rare diseases. A few hundred approved therapies. We know the genetic cause for thousands of them. & we're not waiting. Watch: bit.ly/4w5vo3u

We will release our first quarter 2026 financial results and business update after the market closes on Thursday, May 7 with a conference call at 4:30 pm ET the same day. Learn more on registering here: bridgebio.com/news $BBIO

Shortness of breath. Fatigue. Leg swelling. Carpal tunnel. These aren't always just aging. They can be signs of ATTR-CM, a heart condition that's frequently missed until it's advanced. Today, in partnership with award-winning actor @Morgan_Freeman and @HowardHWhite, a longtime basketball apparel marketing executive, cultural connector, and heart health advocate, we launched Don't Pass On Your Heart Health, a national education campaign to help people recognize the warning signs earlier. Learn more: bit.ly/41IciCx

Incredible news from @SpeakFoundation – the LGMD community now has a national network of Centers of Excellence built patient-first, designed to make sure no one navigates care alone. Congrats to all those involved – you continue to make a difference with patient-led progress!

Three billion base pairs. Infinite reasons to keep going. Happy #WorldDNADay from a team racing to turn beautiful science into treatments for people who need them now.

On #WorldHormoneDay, we are proud to sponsor with @ESEndocrinology and help raise awareness about hormonal imbalances caused by rare diseases. The parathyroid hormone regulates calcium and if not working, this can cause genetic hypoparathyroidism or autosomal dominant hypercalcemia type 1 (ADH1). #BecauseHormonesMatter

Great conversation between our Founder & CEO Neil Kumar and @Roivant CEO @gline on @BiotechTV's Off-Target Effects, covering our hub-and-spoke model how to think about long-term value creation.